SCHEMBL14712975

SCHEMBL14712975

CCN1C(=O)C(=C/C=C/c2ccc(N(C)C)cc2)C(=O)N(CC)C1=S

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.56
APP P05067 11/20 0.55
MAPT P10636 15/20 0.55
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
ALDH1A1 P00352 5/20 0.55
THRB P10828 5/20 0.55
HTT P42858 3/20 0.55
HPGD P15428 2/20 0.55
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
MDM2 Q00987 1/20 0.55
KDM4C Q9H3R0 1/20 0.55
SNCA P37840 9/20 0.54
MAPK1 P28482 4/20 0.48
TDP1 Q9NUW8 4/20 0.48
PKM P14618 3/20 0.48
NPC1 O15118 3/20 0.48
RECQL P46063 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906101 0.95 APP (0.63) METAP1APPMAPTMEN1KMT2A
SCHEMBL14305633 0.95 APP (0.63) METAP1APPMAPTMEN1KMT2A
SCHEMBL14712876 0.85 MAPT (0.59) METAP1APPMAPTMEN1KMT2A
SCHEMBL14712957 0.84 MAPT (0.57) METAP1APPMAPTMEN1KMT2A
SCHEMBL14712905 0.84 MAPT (0.57) METAP1APPMAPTMEN1KMT2A
SCHEMBL14712965 0.83 MAPT (0.64) METAP1APPMAPTMEN1KMT2A
SCHEMBL9970454 0.82 APP (0.71) METAP1APPMAPTMEN1KMT2A
SCHEMBL14712877 0.82 MAPT (0.64) METAP1APPMAPTMEN1KMT2A
SCHEMBL16543009 0.82 MAPT (0.55) APPMAPTMEN1KMT2AL3MBTL1
SCHEMBL16543010 0.76 APP (0.89) METAP1APPMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX METAP1 2044/4885APP 4756/4885MAPT 2828/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 METAP1 2416/4885APP 4689/4885MAPT 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.